{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:14:10Z","timestamp":1788779650508,"version":"build-2803163510"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000774","name":"United States Department of Defense | Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-18-1-0001"],"award-info":[{"award-number":["HDTRA1-18-1-0001"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Open Philanthropy, The Open Philanthropy Project for Universal Flu Vaccine and Improving Protein Design"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Both Zaire\n                    <jats:italic>ebolavirus<\/jats:italic>\n                    (EBOV) and Sudan\n                    <jats:italic>ebolavirus<\/jats:italic>\n                    (SUDV) are members of the genus Ebolavirus and cause outbreaks marked by high fatality rates and repeated spillover from animal reservoirs. Filoviral glycoproteins (GPs) are the primary targets of neutralizing antibodies and form the basis of current vaccines. Here we describe the design, structural characterization, and evaluation of two-component self-assembling icosahedral I53-50 nanoparticles displaying prefusion EBOV or SUDV GP antigens, either individually or in cocktail and mosaic multivalent formats. EBOV-GP-I53-50 and SUDV-GP-I53-50 nanoparticles elicited strong homologous protection in mice and guinea pigs. In the mouse-adapted EBOV model (maEBOV), mosaic and cocktail formulations produced weak survival below that of the matched EBOV-GP-I53-50 GP immunogen. In contrast, in the gpaSUDV guinea pig model (gpSUDV), cocktail and mosaic nanoparticles elicited robust protection against gpSUDV, and detectable antibody responses to both SUDV and EBOV GPs. These findings demonstrate that multivalent GP-I53-50 nanoparticle immunogens can protect rodents from death, severe clinical signs of disease, and weight loss in relevant models. Together with the established clinical safety of the I53-50 platform, these results support continued efforts toward the development of a pan-ebolavirus vaccine.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-76114-1","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T14:26:05Z","timestamp":1786199165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pan-Ebolavirus nanoparticle vaccine provides protection in rodents from lethal infection by Zaire and Sudan viruses"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9354-2276","authenticated-orcid":false,"given":"Connor","family":"Weidle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Brunette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel P.","family":"Wrenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0148-5268","authenticated-orcid":false,"given":"Brooke","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1929-3952","authenticated-orcid":false,"given":"Kenneth D.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha E.","family":"Zak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth E.","family":"Zumbrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell R.","family":"Bakken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8438-2653","authenticated-orcid":false,"given":"Michael","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1617-0464","authenticated-orcid":false,"given":"Sidney","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Skotheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin E.","family":"Correnti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Dye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7896-6217","authenticated-orcid":false,"given":"David","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2978-4692","authenticated-orcid":false,"given":"Neil P.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-7824","authenticated-orcid":false,"given":"Andrew J.","family":"Borst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4264-5125","authenticated-orcid":false,"given":"Lance J.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"76114_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","volume":"6","author":"ST Jacob","year":"2020","unstructured":"Jacob, S. T. et al. Ebola virus disease. Nat. Rev. Dis. Prim. 6, 13 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"76114_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.coph.2021.08.002","volume":"60","author":"EI Ohimain","year":"2021","unstructured":"Ohimain, E. I. & Silas-Olu, D. The 2013\u20132016 Ebola virus disease outbreak in West Africa. Curr. Opin. Pharmacol. 60, 360\u2013365 (2021).","journal-title":"Curr. Opin. Pharmacol."},{"key":"76114_CR3","doi-asserted-by":"publisher","first-page":"e001955","DOI":"10.1136\/bmjgh-2019-001955","volume":"5","author":"S Rugarabamu","year":"2020","unstructured":"Rugarabamu, S. et al. Forty-two years of responding to Ebola virus outbreaks in Sub-Saharan Africa: a review. BMJ Glob. Health 5, e001955 (2020).","journal-title":"BMJ Glob. Health"},{"key":"76114_CR4","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1046\/j.1365-3156.2002.00944.x","volume":"7","author":"SI Okware","year":"2002","unstructured":"Okware, S. I. et al. An outbreak of Ebola in Uganda. Trop. Med. Int. Health 7, 1068\u20131075 (2002).","journal-title":"Trop. Med. Int. Health"},{"key":"76114_CR5","unstructured":"World Health Organization. Ebola outbreak 2018-2020: North Kivu-Ituri. Geneva: World Health Organization; 2020. Available from: https:\/\/www.who.int\/emergencies\/situations\/Ebola-2019-drc-."},{"key":"76114_CR6","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.15585\/mmwr.mm7145a5","volume":"71","author":"T Kiggundu","year":"2022","unstructured":"Kiggundu, T. et al. Notes from the field: outbreak of Ebola virus disease caused by Sudan ebolavirus - Uganda, August-October 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 1457\u20131459 (2022).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"76114_CR7","unstructured":"World Health Organization. Ebola outbreak 2022: Uganda. Geneva: World Health Organization; 2023. Available from: https:\/\/www.who.int\/emergencies\/situations\/ebola-uganda-2022."},{"key":"76114_CR8","unstructured":"World Health Organization. Sudan virus disease - Uganda. Disease Outbreak News; 2025 Apr 26. Available from: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2025-DON566."},{"key":"76114_CR9","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/nm.3702","volume":"20","author":"DA Stanley","year":"2014","unstructured":"Stanley, D. A. et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat. Med. 20, 1126\u20131129 (2014).","journal-title":"Nat. Med."},{"key":"76114_CR10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1126\/science.aab3920","volume":"349","author":"A Marzi","year":"2015","unstructured":"Marzi, A. et al. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014\/15 Ebola virus outbreak strain. Science 349, 739\u2013742 (2015).","journal-title":"Science"},{"key":"76114_CR11","doi-asserted-by":"publisher","unstructured":"Honko, A. N. et al. A single-shot ChAd3 vaccine provides protection from intramuscular and aerosol Sudan virus exposure. bioRxiv https:\/\/doi.org\/10.1101\/2024.02.07.579118 (2024).","DOI":"10.1101\/2024.02.07.579118"},{"key":"76114_CR12","doi-asserted-by":"publisher","unstructured":"Fletcher, P. et al. Single-dose VSV-Sudan virus vaccine protects from lethal Sudan virus infection within one week: a challenge study in macaques. bioRxiv https:\/\/doi.org\/10.1101\/2025.03.26.645555 (2025).","DOI":"10.1101\/2025.03.26.645555"},{"key":"76114_CR13","doi-asserted-by":"publisher","first-page":"e1010078","DOI":"10.1371\/journal.ppat.1010078","volume":"17","author":"C Woolsey","year":"2021","unstructured":"Woolsey, C. & Geisbert, T. W. Current state of Ebola virus vaccines: a snapshot. PLoS Pathog. 17, e1010078 (2021).","journal-title":"PLoS Pathog."},{"key":"76114_CR14","unstructured":"Office of the Commissioner. First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response. U.S. Food and Drug Administration https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health (2020)."},{"key":"76114_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","volume":"389","author":"AM Henao-Restrepo","year":"2017","unstructured":"Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!). Lancet 389, 505\u2013518 (2017).","journal-title":"Lancet"},{"key":"76114_CR16","unstructured":"World Health Organization. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response. Geneva: World Health Organization; 10 Apr 2019. Available from: https:\/\/www.who.int\/publications\/m\/item\/preliminary-results-on-the-efficacy-of-rvsv-zebov-gp-ebola-vaccine-using-the-strategy-in-the-control-of-an-ebola-outbreak."},{"key":"76114_CR17","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa1904387","volume":"391","author":"J-J Muyembe","year":"2024","unstructured":"Muyembe, J.-J. et al. Ebola outbreak response in the DRC with rVSV-ZEBOV-GP ring vaccination. N. Engl. J. Med. 391, 2327\u20132336 (2024).","journal-title":"N. Engl. J. Med."},{"key":"76114_CR18","unstructured":"IAVI applauds Ugandan health authorities on the end of the country\u2019s Sudan virus outbreak. IAVI https:\/\/www.iavi.org\/features\/iavi-applauds-ugandan-health-authorities-on-the-end-of-the-countrys-sudan-virus-outbreak\/ (2025)."},{"key":"76114_CR19","unstructured":"Fast facts about IAVI\u2019s contributions to the 2025 Sudan virus disease outbreak in Uganda. IAVI https:\/\/www.iavi.org\/features\/fast-facts-about-iavis-contributions-to-the-2025-sudan-virus-disease-outbreak-in-uganda\/ (2025)."},{"key":"76114_CR20","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1016\/j.celrep.2020.03.025","volume":"30","author":"L Rutten","year":"2020","unstructured":"Rutten, L. et al. Structure-based design of prefusion-stabilized filovirus glycoprotein trimers. Cell Rep. 30, 4540\u20134550.e3 (2020).","journal-title":"Cell Rep."},{"key":"76114_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2265660","volume":"12","author":"MH Kainulainen","year":"2023","unstructured":"Kainulainen, M. H. et al. Recombinant Sudan virus and evaluation of humoral cross-reactivity between Ebola and Sudan virus glycoproteins after infection or rVSV-\u0394G-ZEBOV-GP vaccination. Emerg. Microbes Infect. 12, 2265660 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"76114_CR22","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","volume":"374","author":"K Ewer","year":"2016","unstructured":"Ewer, K. et al. A monovalent chimpanzee Adenovirus Ebola vaccine boosted with MVA. N. Engl. J. Med. 374, 1635\u20131646 (2016).","journal-title":"N. Engl. J. Med."},{"key":"76114_CR23","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1016\/S2666-5247(23)00001-0","volume":"4","author":"A Marzi","year":"2023","unstructured":"Marzi, A. et al. Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques. Lancet Microbe 4, e171\u2013e178 (2023).","journal-title":"Lancet Microbe"},{"key":"76114_CR24","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm1258","volume":"11","author":"SM Jones","year":"2005","unstructured":"Jones, S. M. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786\u2013790 (2005).","journal-title":"Nat. Med."},{"key":"76114_CR25","unstructured":"World Health Organization. Ebola disease caused by Sudan virus - Uganda. Disease Outbreak News. 26 Sep 2022. Available from: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2022-DON410."},{"key":"76114_CR26","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/vaccines11061120","volume":"11","author":"LA Parish","year":"2023","unstructured":"Parish, L. A., Stavale, E. J., Houchens, C. R. & Wolfe, D. N. Developing vaccines to improve preparedness for filovirus outbreaks: the perspective of the USA Biomedical Advanced Research and Development Authority (BARDA). Vaccines (Basel) 11, 1120 (2023).","journal-title":"Vaccines (Basel)"},{"key":"76114_CR27","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/infdis\/jiae056","volume":"230","author":"S van Tol","year":"2024","unstructured":"van Tol, S. et al. A bivalent Adenovirus-vectored vaccine induces a robust humoral response, but does not protect Cynomolgus macaques against a lethal challenge with Sudan virus. J. Infect. Dis. 230, 1083\u20131092 (2024).","journal-title":"J. Infect. Dis."},{"key":"76114_CR28","doi-asserted-by":"publisher","first-page":"101022","DOI":"10.1016\/j.lanmic.2024.101022","volume":"6","author":"D Jenkin","year":"2025","unstructured":"Jenkin, D. et al. Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial. Lancet Microbe 6, 101022 (2025).","journal-title":"Lancet Microbe"},{"key":"76114_CR29","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1128\/CVI.00467-09","volume":"17","author":"WD Pratt","year":"2010","unstructured":"Pratt, W. D. et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin. Vaccin. Immunol. 17, 572\u2013581 (2010).","journal-title":"Clin. Vaccin. Immunol."},{"key":"76114_CR30","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.1128\/JVI.00561-09","volume":"83","author":"TW Geisbert","year":"2009","unstructured":"Geisbert, T. W. et al. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J. Virol. 83, 7296\u20137304 (2009).","journal-title":"J. Virol."},{"key":"76114_CR31","doi-asserted-by":"publisher","first-page":"703986","DOI":"10.3389\/fimmu.2021.703986","volume":"12","author":"AT Lehrer","year":"2021","unstructured":"Lehrer, A. T. et al. Recombinant protein filovirus vaccines protect Cynomolgus macaques from Ebola, Sudan, and Marburg viruses. Front. Immunol. 12, 703986 (2021).","journal-title":"Front. Immunol."},{"key":"76114_CR32","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.vaccine.2023.12.053","volume":"42","author":"A To","year":"2024","unstructured":"To, A. et al. Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection. Vaccine 42, 598\u2013607 (2024).","journal-title":"Vaccine"},{"key":"76114_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00330-7","volume":"6","author":"B Nguyen","year":"2021","unstructured":"Nguyen, B. & Tolia, N. H. Protein-based antigen presentation platforms for nanoparticle vaccines. NPJ Vaccines 6, 70 (2021).","journal-title":"NPJ Vaccines"},{"key":"76114_CR34","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.immuni.2020.08.001","volume":"53","author":"Y Kato","year":"2020","unstructured":"Kato, Y. et al. Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo. Immunity 53, 548\u2013563.e8 (2020).","journal-title":"Immunity"},{"key":"76114_CR35","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367\u20131382.e17 (2020).","journal-title":"Cell"},{"key":"76114_CR36","doi-asserted-by":"publisher","first-page":"eadg7404","DOI":"10.1126\/scitranslmed.adg7404","volume":"15","author":"Y Feng","year":"2023","unstructured":"Feng, Y. et al. Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine. Sci. Transl. Med. 15, eadg7404 (2023).","journal-title":"Sci. Transl. Med."},{"key":"76114_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41586-021-03530-2","volume":"594","author":"PS Arunachalam","year":"2021","unstructured":"Arunachalam, P. S. et al. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature 594, 253\u2013258 (2021).","journal-title":"Nature"},{"key":"76114_CR38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1126\/science.aaf8818","volume":"353","author":"JB Bale","year":"2016","unstructured":"Bale, J. B. et al. Accurate design of megadalton-scale two-component icosahedral protein complexes. Science 353, 389\u2013394 (2016).","journal-title":"Science"},{"key":"76114_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21251-y","volume":"12","author":"AJ Wargacki","year":"2021","unstructured":"Wargacki, A. J. et al. Complete and cooperative in vitro assembly of computationally designed self-assembling protein nanomaterials. Nat. Commun. 12, 883 (2021).","journal-title":"Nat. Commun."},{"key":"76114_CR40","doi-asserted-by":"publisher","first-page":"S430","DOI":"10.1086\/520583","volume":"196","author":"KL Warfield","year":"2007","unstructured":"Warfield, K. L. et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 196, S430\u2013S437 (2007).","journal-title":"J. Infect. Dis."},{"key":"76114_CR41","doi-asserted-by":"publisher","first-page":"e2316960121","DOI":"10.1073\/pnas.2316960121","volume":"121","author":"D Xu","year":"2024","unstructured":"Xu, D. et al. Design of universal Ebola virus vaccine candidates via immunofocusing. Proc. Natl. Acad. Sci. USA. 121, e2316960121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"76114_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22867-w","volume":"12","author":"L He","year":"2021","unstructured":"He, L. et al. Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines. Nat. Commun. 12, 2633 (2021).","journal-title":"Nat. Commun."},{"key":"76114_CR43","doi-asserted-by":"publisher","first-page":"942897","DOI":"10.3389\/fimmu.2022.942897","volume":"13","author":"AE Powell","year":"2022","unstructured":"Powell, A. E. et al. Multimerization of Ebola GP\u0394mucin on protein nanoparticle vaccines has minimal effect on elicitation of neutralizing antibodies. Front. Immunol. 13, 942897 (2022).","journal-title":"Front. Immunol."},{"key":"76114_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz6225","volume":"6","author":"L He","year":"2020","unstructured":"He, L. et al. Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines. Sci. Adv. 6, eaaz6225 (2020).","journal-title":"Sci. Adv."},{"key":"76114_CR45","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/nature18010","volume":"535","author":"Y Hsia","year":"2016","unstructured":"Hsia, Y. et al. Design of a hyperstable 60-subunit protein dodecahedron. [corrected]. Nature 535, 136\u2013139 (2016).","journal-title":"Nature"},{"key":"76114_CR46","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41590-018-0305-x","volume":"20","author":"M Kanekiyo","year":"2019","unstructured":"Kanekiyo, M. et al. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat. Immunol. 20, 362\u2013372 (2019).","journal-title":"Nat. Immunol."},{"key":"76114_CR47","doi-asserted-by":"publisher","first-page":"5432","DOI":"10.1016\/j.cell.2021.09.015","volume":"184","author":"AC Walls","year":"2021","unstructured":"Walls, A. C. et al. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell 184, 5432\u20135447.e16 (2021).","journal-title":"Cell"},{"key":"76114_CR48","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41586-021-03365-x","volume":"592","author":"S Boyoglu-Barnum","year":"2021","unstructured":"Boyoglu-Barnum, S. et al. Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature 592, 623\u2013628 (2021).","journal-title":"Nature"},{"key":"76114_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq0839","volume":"377","author":"AA Cohen","year":"2022","unstructured":"Cohen, A. A. et al. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science 377, eabq0839 (2022).","journal-title":"Science"},{"key":"76114_CR50","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","volume":"176","author":"J Marcandalli","year":"2019","unstructured":"Marcandalli, J. et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell 176, 1420\u20131431.e17 (2019).","journal-title":"Cell"},{"key":"76114_CR51","doi-asserted-by":"publisher","first-page":"5762","DOI":"10.1073\/pnas.95.10.5762","volume":"95","author":"VE Volchkov","year":"1998","unstructured":"Volchkov, V. E., Feldmann, H., Volchkova, V. A. & Klenk, H. D. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl. Acad. Sci. USA. 95, 5762\u20135767 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"76114_CR52","doi-asserted-by":"publisher","first-page":"12463","DOI":"10.1128\/JVI.76.24.12463-12472.2002","volume":"76","author":"SA Jeffers","year":"2002","unstructured":"Jeffers, S. A., Sanders, D. A. & Sanchez, A. Covalent modifications of the Ebola virus glycoprotein. J. Virol. 76, 12463\u201312472 (2002).","journal-title":"J. Virol."},{"key":"76114_CR53","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.sbi.2009.05.004","volume":"19","author":"JE Lee","year":"2009","unstructured":"Lee, J. E. & Saphire, E. O. Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Curr. Opin. Struct. Biol. 19, 408\u2013417 (2009).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"76114_CR54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1743-422X-9-32","volume":"9","author":"W Ou","year":"2012","unstructured":"Ou, W. et al. Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain. Virol. J. 9, 32 (2012).","journal-title":"Virol. J."},{"key":"76114_CR55","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s42003-022-03767-1","volume":"5","author":"W Peng","year":"2022","unstructured":"Peng, W. et al. Glycan shield of the ebolavirus envelope glycoprotein GP. Commun. Biol. 5, 785 (2022).","journal-title":"Commun. Biol."},{"key":"76114_CR56","doi-asserted-by":"publisher","first-page":"S347","DOI":"10.1086\/520581","volume":"196","author":"A Takada","year":"2007","unstructured":"Takada, A., Ebihara, H., Feldmann, H., Geisbert, T. W. & Kawaoka, Y. Epitopes required for antibody-dependent enhancement of Ebola virus infection. J. Infect. Dis. 196, S347\u2013S356 (2007).","journal-title":"J. Infect. Dis."},{"key":"76114_CR57","doi-asserted-by":"publisher","first-page":"e1004731","DOI":"10.1371\/journal.ppat.1004731","volume":"11","author":"S Moller-Tank","year":"2015","unstructured":"Moller-Tank, S. & Maury, W. Ebola virus entry: a curious and complex series of events. PLoS Pathog. 11, e1004731 (2015).","journal-title":"PLoS Pathog."},{"key":"76114_CR58","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature10348","volume":"477","author":"JE Carette","year":"2011","unstructured":"Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 340\u2013343 (2011).","journal-title":"Nature"},{"key":"76114_CR59","doi-asserted-by":"publisher","first-page":"E7987","DOI":"10.1073\/pnas.1708052114","volume":"114","author":"J Lee","year":"2017","unstructured":"Lee, J. et al. Structure of the Ebola virus envelope protein MPER\/TM domain and its interaction with the fusion loop explains their fusion activity. Proc. Natl. Acad. Sci. Usa. 114, E7987\u2013E7996 (2017).","journal-title":"Proc. Natl. Acad. Sci. Usa."},{"key":"76114_CR60","doi-asserted-by":"crossref","unstructured":"Gire, S. K. et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345, 1369\u20131372 (2014).","DOI":"10.1126\/science.1259657"},{"key":"76114_CR61","doi-asserted-by":"crossref","unstructured":"Fels, J. M. et al. A glycoprotein mutation that emerged during the 2013-2016 Ebola virus epidemic alters proteolysis and accelerates membrane fusion. MBio 12, (2021).","DOI":"10.1128\/mBio.03616-20"},{"key":"76114_CR62","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1110\/ps.036111.108","volume":"17","author":"A Bhardwaj","year":"2008","unstructured":"Bhardwaj, A., Walker-Kopp, N., Wilkens, S. & Cingolani, G. Foldon-guided self-assembly of ultra-stable protein fibers. Protein Sci. 17, 1475\u20131485 (2008).","journal-title":"Protein Sci."},{"key":"76114_CR63","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature18615","volume":"535","author":"Y Zhao","year":"2016","unstructured":"Zhao, Y. et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 535, 169\u2013172 (2016).","journal-title":"Nature"},{"key":"76114_CR64","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature07082","volume":"454","author":"JE Lee","year":"2008","unstructured":"Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177\u2013182 (2008).","journal-title":"Nature"},{"key":"76114_CR65","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1021\/acs.jmedchem.7b01249","volume":"61","author":"J Ren","year":"2018","unstructured":"Ren, J., Zhao, Y., Fry, E. E. & Stuart, D. I. Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection. J. Med. Chem. 61, 724\u2013733 (2018).","journal-title":"J. Med. Chem."},{"key":"76114_CR66","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr706","volume":"39","author":"AD Bandaranayake","year":"2011","unstructured":"Bandaranayake, A. D. et al. Daedalus: a robust, turnkey platform for rapid production of decigram quantities of active recombinant proteins in human cell lines using novel lentiviral vectors. Nucleic Acids Res. 39, e143 (2011).","journal-title":"Nucleic Acids Res."},{"key":"76114_CR67","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1021\/acs.jmedchem.8b01328","volume":"62","author":"F Shaikh","year":"2019","unstructured":"Shaikh, F. et al. Structure-based in silico screening identifies a potent Ebolavirus inhibitor from a traditional Chinese medicine library. J. Med. Chem. 62, 2928\u20132937 (2019).","journal-title":"J. Med. Chem."},{"key":"76114_CR68","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1021\/acsmedchemlett.0c00025","volume":"11","author":"MB Plewe","year":"2020","unstructured":"Plewe, M. B. et al. Discovery of adamantane carboxamides as Ebola virus cell entry and glycoprotein inhibitors. ACS Med. Chem. Lett. 11, 1160\u20131167 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"76114_CR69","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1021\/acs.jmedchem.8b00350","volume":"61","author":"Y Zhao","year":"2018","unstructured":"Zhao, Y. et al. Structures of Ebola virus glycoprotein complexes with tricyclic antidepressant and antipsychotic drugs. J. Med. Chem. 61, 4938\u20134945 (2018).","journal-title":"J. Med. Chem."},{"key":"76114_CR70","doi-asserted-by":"publisher","first-page":"808047","DOI":"10.3389\/fimmu.2021.808047","volume":"12","author":"CD Murin","year":"2021","unstructured":"Murin, C. D., Gilchuk, P., Crowe, J. E. Jr & Ward, A. B. Structural biology illuminates molecular determinants of broad ebolavirus neutralization by human antibodies for pan-ebolavirus therapeutic development. Front. Immunol. 12, 808047 (2021).","journal-title":"Front. Immunol."},{"key":"76114_CR71","doi-asserted-by":"publisher","first-page":"S204","DOI":"10.1093\/infdis\/jiv201","volume":"212","author":"NJ Lennemann","year":"2015","unstructured":"Lennemann, N. J., Walkner, M., Berkebile, A. R., Patel, N. & Maury, W. The role of conserved N-linked glycans on Ebola virus glycoprotein 2. J. Infect. Dis. 212, S204\u2013S209 (2015).","journal-title":"J. Infect. Dis."},{"key":"76114_CR72","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1097-2765(00)80159-8","volume":"2","author":"W Weissenhorn","year":"1998","unstructured":"Weissenhorn, W., Carf\u00ed, A., Lee, K. H., Skehel, J. J. & Wiley, D. C. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. Cell 2, 605\u2013616 (1998).","journal-title":"Mol. Cell"},{"key":"76114_CR73","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1002\/pro.688","volume":"20","author":"JS Harrison","year":"2011","unstructured":"Harrison, J. S., Higgins, C. D., Chandran, K. & Lai, J. R. Designed protein mimics of the Ebola virus glycoprotein GP2 \u03b1-helical bundle: stability and pH effects: Mimicry of the Ebola virus GP2 \u03b1-Helical Bundle. Protein Sci. 20, 1587\u20131596 (2011).","journal-title":"Protein Sci."},{"key":"76114_CR74","doi-asserted-by":"publisher","first-page":"S248","DOI":"10.1086\/514292","volume":"179","author":"M Bray","year":"1999","unstructured":"Bray, M., Davis, K., Geisbert, T., Schmaljohn, C. & Huggins, J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 179, S248\u2013S258 (1999).","journal-title":"J. Infect. Dis."},{"key":"76114_CR75","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nature20108","volume":"540","author":"Y Hsia","year":"2016","unstructured":"Hsia, Y. et al. Corrigendum: Design of a hyperstable 60-subunit protein icosahedron. Nature 540, 150 (2016).","journal-title":"Nature"},{"key":"76114_CR76","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jmb.2007.08.021","volume":"373","author":"S Klinke","year":"2007","unstructured":"Klinke, S. et al. Structural and kinetic properties of lumazine synthase isoenzymes in the order Rhizobiales. J. Mol. Biol. 373, 664\u2013680 (2007).","journal-title":"J. Mol. Biol."},{"key":"76114_CR77","doi-asserted-by":"publisher","first-page":"105493","DOI":"10.1016\/j.antiviral.2022.105493","volume":"210","author":"SB Bradfute","year":"2023","unstructured":"Bradfute, S. B. History and impact of the mouse-adapted Ebola virus model. Antivir. Res. 210, 105493 (2023).","journal-title":"Antivir. Res."},{"key":"76114_CR78","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1128\/JVI.02331-15","volume":"90","author":"G Wong","year":"2015","unstructured":"Wong, G. et al. Development and characterization of a guinea pig-adapted Sudan virus. J. Virol. 90, 392\u2013399 (2015).","journal-title":"J. Virol."},{"key":"76114_CR79","doi-asserted-by":"publisher","first-page":"S648","DOI":"10.1093\/infdis\/jiad266","volume":"228","author":"DC Malherbe","year":"2023","unstructured":"Malherbe, D. C. et al. A single-dose intranasal combination panebolavirus vaccine. J. Infect. Dis. 228, S648\u2013S659 (2023).","journal-title":"J. Infect. Dis."},{"key":"76114_CR80","doi-asserted-by":"publisher","first-page":"710263","DOI":"10.3389\/fimmu.2021.710263","volume":"12","author":"D Ellis","year":"2021","unstructured":"Ellis, D. et al. Stabilization of the SARS-CoV-2 Spike receptor-binding domain using deep mutational scanning and structure-based design. Front. Immunol. 12, 710263 (2021).","journal-title":"Front. Immunol."},{"key":"76114_CR81","doi-asserted-by":"publisher","first-page":"115036","DOI":"10.1016\/j.celrep.2024.115036","volume":"43","author":"CW Chao","year":"2024","unstructured":"Chao, C. W. et al. Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV. Cell Rep. 43, 115036 (2024).","journal-title":"Cell Rep."},{"key":"76114_CR82","doi-asserted-by":"publisher","first-page":"100658","DOI":"10.1016\/j.xcrm.2022.100658","volume":"3","author":"H Malhi","year":"2022","unstructured":"Malhi, H. et al. Immunization with a self-assembling nanoparticle vaccine displaying EBV gH\/gL protects humanized mice against lethal viral challenge. Cell Rep. Med. 3, 100658 (2022).","journal-title":"Cell Rep. Med."},{"key":"76114_CR83","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.vaccine.2016.02.033","volume":"34","author":"KL Bengtsson","year":"2016","unstructured":"Bengtsson, K. L. et al. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola\/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine 34, 1927\u20131935 (2016).","journal-title":"Vaccine"},{"key":"76114_CR84","first-page":"6","volume":"14","author":"T Hahn","year":"2015","unstructured":"Hahn, T. et al. Rapid manufacture and release of a GMP batch of Zaire ebolavirus glycoprotein vaccine made using recombinant Baculovirus-Sf9 insect cell culture technology. Bioprocess. (Williamsbg. Va.) 14, 6\u201314 (2015).","journal-title":"Bioprocess. (Williamsbg. Va.)"},{"key":"76114_CR85","doi-asserted-by":"publisher","first-page":"8855","DOI":"10.1021\/acsnano.8b02805","volume":"12","author":"TUJ Bruun","year":"2018","unstructured":"Bruun, T. U. J., Andersson, A.-M. C., Draper, S. J. & Howarth, M. Engineering a rugged nanoscaffold to enhance Plug-and-Display vaccination. ACS Nano 12, 8855\u20138866 (2018).","journal-title":"ACS Nano"},{"key":"76114_CR86","doi-asserted-by":"publisher","first-page":"E690","DOI":"10.1073\/pnas.1115485109","volume":"109","author":"B Zakeri","year":"2012","unstructured":"Zakeri, B. et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc. Natl. Acad. Sci. USA. 109, E690\u2013E697 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"76114_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00622-0","volume":"8","author":"C Jacob-Dolan","year":"2023","unstructured":"Jacob-Dolan, C. et al. Immunogenicity and protective efficacy of GBP510\/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques. NPJ Vaccines 8, 23 (2023).","journal-title":"NPJ Vaccines"},{"key":"76114_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66367-7","volume":"16","author":"Y-Z Lee","year":"2025","unstructured":"Lee, Y.-Z. et al. Rational design of next-generation filovirus vaccines combining glycoprotein stabilization and nanoparticle display with glycan modification. Nat. Commun. 16, 11368 (2025).","journal-title":"Nat. Commun."},{"key":"76114_CR89","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1016\/j.xphs.2020.09.011","volume":"109","author":"KB Preston","year":"2020","unstructured":"Preston, K. B. et al. Preservation of quaternary structure in thermostable, lyophilized filovirus glycoprotein vaccines: a search for stability-indicating assays. J. Pharm. Sci. 109, 3716\u20133727 (2020).","journal-title":"J. Pharm. Sci."},{"key":"76114_CR90","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1128\/JVI.01956-08","volume":"83","author":"D Dube","year":"2009","unstructured":"Dube, D. et al. The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J. Virol. 83, 2883\u20132891 (2009).","journal-title":"J. Virol."},{"key":"76114_CR91","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1128\/JVI.05708-11","volume":"86","author":"M Brecher","year":"2012","unstructured":"Brecher, M. et al. Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J. Virol. 86, 364\u2013372 (2012).","journal-title":"J. Virol."},{"key":"76114_CR92","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2217\/fvl.09.56","volume":"4","author":"JE Lee","year":"2009","unstructured":"Lee, J. E. & Saphire, E. O. Ebolavirus glycoprotein structure and mechanism of entry. Future Virol. 4, 621\u2013635 (2009).","journal-title":"Future Virol."},{"key":"76114_CR93","doi-asserted-by":"publisher","first-page":"113366","DOI":"10.1016\/j.celrep.2023.113366","volume":"42","author":"X Yu","year":"2023","unstructured":"Yu, X. et al. The evolution and determinants of neutralization of potent head-binding antibodies against Ebola virus. Cell Rep. 42, 113366 (2023).","journal-title":"Cell Rep."},{"key":"76114_CR94","doi-asserted-by":"publisher","first-page":"10958","DOI":"10.1128\/JVI.00870-14","volume":"88","author":"EEH Tran","year":"2014","unstructured":"Tran, E. E. H. et al. Spatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography. J. Virol. 88, 10958\u201310962 (2014).","journal-title":"J. Virol."},{"key":"76114_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/srep46374","volume":"7","author":"DR Beniac","year":"2017","unstructured":"Beniac, D. R. & Booth, T. F. Structure of the Ebola virus glycoprotein spike within the virion envelope at 11 \u00c5 resolution. Sci. Rep. 7, 46374 (2017).","journal-title":"Sci. Rep."},{"key":"76114_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09732-7","volume":"10","author":"LB King","year":"2019","unstructured":"King, L. B. et al. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk. Nat. Commun. 10, 1788 (2019).","journal-title":"Nat. Commun."},{"key":"76114_CR97","doi-asserted-by":"publisher","first-page":"101339","DOI":"10.1016\/j.coviro.2023.101339","volume":"61","author":"P Rijal","year":"2023","unstructured":"Rijal, P. & Donnellan, F. R. A review of broadly protective monoclonal antibodies to treat Ebola virus disease. Curr. Opin. Virol. 61, 101339 (2023).","journal-title":"Curr. Opin. Virol."},{"key":"76114_CR98","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41564-018-0157-z","volume":"3","author":"AI Flyak","year":"2018","unstructured":"Flyak, A. I. et al. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2\u2013MPER region. Nat. Microbiol. 3, 670\u2013677 (2018).","journal-title":"Nat. Microbiol."},{"key":"76114_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010518","volume":"18","author":"CT Schoeder","year":"2022","unstructured":"Schoeder, C. T. et al. Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region. PLoS Pathog. 18, e1010518 (2022).","journal-title":"PLoS Pathog."},{"key":"76114_CR100","doi-asserted-by":"crossref","unstructured":"Gasteiger, E. et al. Protein Identification and Analysis Tools on the ExPASy Server. In The Proteomics Protocols Handbook (ed. Walker, J. M.) 571\u2013607 (Humana Press, Totowa, NJ, 2005).","DOI":"10.1385\/1-59259-890-0:571"},{"key":"76114_CR101","doi-asserted-by":"publisher","first-page":"8828","DOI":"10.1128\/JVI.79.14.8828-8834.2005","volume":"79","author":"DH Barouch","year":"2005","unstructured":"Barouch, D. H. et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J. Virol. 79, 8828\u20138834 (2005).","journal-title":"J. Virol."},{"key":"76114_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00982-1","volume":"9","author":"MC Miranda","year":"2024","unstructured":"Miranda, M. C. et al. Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens. NPJ Vaccines 9, 184 (2024).","journal-title":"NPJ Vaccines"},{"key":"76114_CR103","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jsb.2005.03.010","volume":"151","author":"C Suloway","year":"2005","unstructured":"Suloway, C. et al. Automated molecular microscopy: the new Legion system. J. Struct. Biol. 151, 41\u201360 (2005).","journal-title":"J. Struct. Biol."},{"key":"76114_CR104","doi-asserted-by":"publisher","first-page":"107745","DOI":"10.1016\/j.jsb.2021.107745","volume":"213","author":"M Sun","year":"2021","unstructured":"Sun, M. et al. Practical considerations for using K3 cameras in CDS mode for high-resolution and high-throughput single particle cryo-EM. J. Struct. Biol. 213, 107745 (2021).","journal-title":"J. Struct. Biol."},{"key":"76114_CR105","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"76114_CR106","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s42003-021-02399-1","volume":"4","author":"R Sanchez-Garcia","year":"2021","unstructured":"Sanchez-Garcia, R. et al. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Commun. Biol. 4, 874 (2021).","journal-title":"Commun. Biol."},{"key":"76114_CR107","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2013a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"76114_CR108","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1107\/S2059798318002425","volume":"74","author":"TI Croll","year":"2018","unstructured":"Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D. Struct. Biol. 74, 519\u2013530 (2018).","journal-title":"Acta Crystallogr. D. Struct. Biol."},{"key":"76114_CR109","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"76114_CR110","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of coot. Acta Crystallogr. D. Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"76114_CR111","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D. Struct. Biol. 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. D. Struct. Biol."},{"key":"76114_CR112","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/pro.3786","volume":"29","author":"MG Prisant","year":"2020","unstructured":"Prisant, M. G., Williams, C. J., Chen, V. B., Richardson, J. S. & Richardson, D. C. New tools in MolProbity validation: CaBLAM for CryoEM backbone, UnDowser to rethink \u2018waters,\u2019 and NGL Viewer to recapture online 3D graphics. Protein Sci. 29, 315\u2013329 (2020).","journal-title":"Protein Sci."},{"key":"76114_CR113","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."},{"key":"76114_CR114","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00524-24","volume":"98","author":"I Bagdonaite","year":"2024","unstructured":"Bagdonaite, I. et al. Targeting host O-linked glycan biosynthesis affects Ebola virus replication efficiency and reveals differential GalNAc-T acceptor site preferences on the Ebola virus glycoprotein. J. Virol. 98, e0052424 (2024).","journal-title":"J. Virol."},{"key":"76114_CR115","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0168-1702(93)90063-S","volume":"29","author":"A Sanchez","year":"1993","unstructured":"Sanchez, A., Kiley, M. P., Holloway, B. P. & Auperin, D. D. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res. 29, 215\u2013240 (1993).","journal-title":"Virus Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76114-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76114-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76114-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:05:36Z","timestamp":1788779136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76114-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76114"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76114-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.J.S, N.P.K, D.B., L.C., A.J.B., C.W., and N.B. are listed as inventors or major contributors to records of innovation at the University of Washington. The King and Baker laboratories have received unrelated sponsored research agreements from Pfizer and Merck, respectively. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The opinions, interpretations, conclusions, and recommendations presented are those of the authors and are not necessarily endorsed by the U.S. Army or Department of Defense. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The use of trade or manufacturers\u2019 names in this publication does not constitute an official endorsement of any commercial products. This report may not be cited for the purposes of advertisement. Contractor affiliation of some authors does not imply endorsement by the U.S. Government of any contractor.","order":2,"name":"Ethics","label":"Disclaimers","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal studies were conducted under IACUC-approved protocols in compliance with the Animal Welfare Act, Public Health Service Policy, and other applicable federal statutes and regulations relating to animals and experiments involving animals. The facility where these studies was conducted (USAMRIID) is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 2011. The animal study protocol was approved by the Institutional Animal Care and Use Committee of USAMRIID (protocol number AP-19-005, 05 February 2019).","order":3,"name":"Ethics","label":"Institutional review board statement","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9541"}}